HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Milestone Pharmaceuticals (NASDAQ:MIST), maintaining a $25 price target.

February 26, 2024 | 4:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Milestone Pharmaceuticals with a $25 price target.
The reiteration of a Buy rating and maintenance of a $25 price target by a reputable analyst firm like HC Wainwright & Co. could instill confidence among investors and potentially lead to a positive short-term impact on MIST's stock price. Analyst endorsements often influence investor perceptions and can lead to increased buying activity.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100